E Fund Management’s ImmunityBio IBRX Stock Holding History

E Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$447K	Sell	51,072 -19,149	-27%	-$145K	0.01%	299
2026 Q1	$539K	Buy	+70,221	New	+$481K	0.02%	280
2025 Q2	$74.2K	Sell	28,108 -2,223	-7%	-$5.98K	﹤0.01%	380
2025 Q1	$91.3K	Sell	30,331 -8,569	-22%	-$26K	﹤0.01%	386
2024 Q4	$99.6K	Buy	38,900 +9,622	+33%	+$40.1K	0.01%	378
2024 Q3	$109K	Buy	29,278 +2,820	+11%	+$13.1K	0.01%	339
2024 Q2	$167K	Sell	26,458 -35,464	-57%	-$234K	0.01%	300
2024 Q1	$333K	Buy	61,922 +22,428	+57%	+$102K	0.02%	263
2023 Q4	$198K	Buy	+39,494	New	+$124K	0.01%	286
2023 Q1	–	Sell	-24,706	Closed	-$125K	–	344
2022 Q4	$125K	Sell	24,706 -3,098	-11%	-$17K	0.01%	321
2022 Q3	$138K	Buy	+27,804	New	+$127K	0.01%	320
2022 Q2	–	Sell	-22,816	Closed	-$128K	–	336
2022 Q1	$128K	Buy	22,816 +7,933	+53%	+$48.7K	﹤0.01%	312
2021 Q4	$90K	Buy	14,883 +2,245	+18%	+$16.9K	﹤0.01%	289
2021 Q3	$123K	Buy	+12,638	New	+$139K	0.01%	254

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

E Fund Management's IBRX Position: Q2 2026 in Review

E Fund Management reduced its ImmunityBio (IBRX) stake by 27% in Q2 2026, selling an estimated $145K and leaving 51,072 shares worth $447K. The position accounts for 0.01% of the portfolio, ranked #299.

E Fund Management first reported a position in IBRX in Q3 2021 and has held it in 14 quarters since. The position peaked at $539K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

E Fund Management held 51,072 shares of ImmunityBio worth $447K as of Q2 2026.
E Fund Management sold 19,149 ImmunityBio shares in Q2 2026, an estimated $145K.
ImmunityBio made up 0.01% of E Fund Management's portfolio in Q2 2026, its #299 holding.
E Fund Management first reported a position in ImmunityBio in Q3 2021 and has held it in 14 quarters since.
E Fund Management's ImmunityBio position peaked at $539K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.